Mechanism Of Protection Of Islet Beta Cells From T1D By Heparan Sulfate
Funder
National Health and Medical Research Council
Funding Amount
$602,453.00
Summary
Type 1 diabetes (T1D) is an autoimmune disease which destroys the insulin-producing beta cells in the pancreas. Current insulin therapy does not prevent the development of serious secondary complications. We have discovered that beta cells require a complex sugar (heparan sulfate; HS) for their survival and that T1D is prevented when an enzyme, heparanase, that degrades HS is inhibited. Understanding these mechanisms will identify new therapeutic strategies for preventing T1D progression.
Colon cancer causes about 4,000 deaths per year in Australia. A better understanding of the biology of colon cancer will lead to new therapeutics that will aim to overcome the treatment resistance. This project is focused on understanding how a novel protein SLIRP regulates colon cancer growth, and will investigate the mechanisms for its protective effects on the disease. If successful, these studies could provide the foundation for targeting SLIRP for therapeutics.
Impact Of Islet Beta Cell Heparan Sulfate In Type 2 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$576,777.00
Summary
Type 2 diabetes (T2D) is a chronic metabolic disease which ultimately leads to the death of insulin-producing islet beta cells, elevated blood sugar levels and daily insulin injections. Since beta cells require the complex sugar heparan sulfate (HS) for survival, we will investigate whether beta cell failure in T2D results from defective HS production. HS replacement will be evaluated as a new therapeutic strategy for preserving beta cell function and preventing the need for insulin injections.
Dissecting The Function Of Heparanase In Inflammatory Disease Using Genetic Tissue-specific Ablation
Funder
National Health and Medical Research Council
Funding Amount
$580,848.00
Summary
This project aims to define the role of the enzyme heparanase in a number of important diseases, namely Inflammatory-autoimmune diseases such as multiple scelorosis and rheumatiod arthritis, and the growth and spread of cancer. Heparanase has been implicated for many years in promoting these diseases however its precise contribution has not beed defined. These studies will provide definitive information whether heparanase is a valid therapuetic target in these important disease settings.